<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100848">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01937559</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00021253</org_study_id>
    <nct_id>NCT01937559</nct_id>
  </id_info>
  <brief_title>Topical Tranexamic Acid (TXA) in Joint Arthroplasty</brief_title>
  <official_title>Topical Application of Tranexamic Acid in Joint Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hawkins Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hawkins Foundation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in
      decreasing blood loss following both shoulder arthroplasty and primary total hip
      arthroplasty.  TXA functions to decrease blood loss by affecting the blood clotting system
      within the body.  The investigators hypothesize that topical application of TXA prior to
      closure reduces postoperative bleeding as measured by absolute changes in postoperative
      hemoglobin levels and surgical drain output.  In addition, use of topically applied
      tranexaminic acid may reduce the need for transfusions, the rates of hematomas, infections,
      and length of hospital stay.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Post-operative blood loss</measure>
    <time_frame>Duration of hospital stay</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood loss will be calculated as the difference between the preoperative hemoglobin and the lowest postoperative hemoglobin during the hospital stay or the lowest postoperative hemoglobin prior to blood transfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative blood transfusions</measure>
    <time_frame>Duration of surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood units transfused</measure>
    <time_frame>Duration of surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical infections</measure>
    <time_frame>Duration of hospital stay</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Duration of hospital stay</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until start of rehabilitation program</measure>
    <time_frame>Up to 3 weeks post-surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative changes in joint function</measure>
    <time_frame>Duration of hospital stay</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increase or reduction in ROM of the knee will be accounted for during the patient's stay at the hospital post-surgery.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Shoulder outcome scores</measure>
    <time_frame>6 months post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Shoulder outcome scores will include a PENN derived ASES form.</description>
  </other_outcome>
  <other_outcome>
    <measure>General outcome scores</measure>
    <time_frame>6 months post-surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>General outcome measures will include EQ-5D, GROC and SANE forms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hip outcome scores</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Hip outcome measurements will include Harris Hip score and the WOMAC forms.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Shoulder Arthroplasty</condition>
  <condition>Primary Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Antifibrinolytic agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexaminic acid (TXA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tranexaminic Acid (TXA)</intervention_name>
    <description>1.5g of TXA in 100ml normal saline solution</description>
    <arm_group_label>Antifibrinolytic agent</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Shoulders: All adult patients over the age of 18 scheduled for a primary total
             arthroplasty or a primary reverse shoulder arthroplasty will be eligible for
             inclusion in the study.

        Hips:  All adult patients over the age of 18 scheduled for a primary total hip
        arthroplasty will be eligible for inclusion in the study.

        Exclusion Criteria:

          -  allergy to TXA, refusal of blood products, preoperative use of anticoagulant therapy
             within 5 days of surgery, history of seizures, renal failure (creatine clearance
             &lt;30ml/min), bleeding disorders, venous thromboembolism (deep vein thrombosis and/or
             pulmonary embolism), significant cardiac history (myocardial infarction, angina,
             stroke, lower limb ischemia), or perioperative anemia (hemoglobin &lt;11g/dl in females
             and &lt; 12g/dl in males).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory P Colbath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steadman Hawkins Clinic of the Carolinas - Greenville Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlisle Shealy, BS</last_name>
    <phone>864-454-7458</phone>
    <email>carlisle.shealy@hawkinsfoundation.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steadman Hawkins Clinic of the Carolinas - Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlisle Shealy, MD</last_name>
      <phone>864-454-7458</phone>
      <email>carlisle.shealy@hawkinsfoundation.com</email>
    </contact>
    <investigator>
      <last_name>Gregory P Colbath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard J Hawkins, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael J Kissenberth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Tolan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brandon Broome, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brayton R Shirley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phillip H Wessinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 7, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tranexaminic acid (TXA)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antifibrinolytic Agents</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
